

REMARKS

Applicants request entry of the above preliminary amendment. Applicants have amended claims 1-13 and added new claims 14-15.

Regarding amendments to claims 1-3, support for the term “purified” can be found in page 18, lines 8-13 of the application as filed which describes the purification of the crude synthetic product to obtain purified (4S)-methyl hexanoic kahalalide, a specific type of 4-methyl hexanoic kahalalide F.

With regards to claim 8, support for the phrase “combining a compound according to either one of claims 1 or 2 with a pharmaceutically acceptable carrier, vehicle or diluent” is supported by the disclosure on page 10, line 22 to page 11, line 8 which describes “bringing into association the active ingredient with the carrier(s) or excipient(s).”

Support for newly added claims 14-15 are found in pages 27-29, which describe the experimental results showing that (4S)-methyl hexanoic kahalalide F is more effective against cancer, specifically hepatocellular carcinoma, human liver adenocarcinoma, breast cancer, and prostate cancer, than 5-methyl hexanoic kahalalide F. In particular, page 27, lines 16-17 of the specification state that “(4S)-methylhexanoic KF clearly appears to be the more potent isomer in breast xenografts”; page 28, line 15 indicates that “significantly more efficacy was achieved with (4S)-methylhexanoic KF” against prostate cancer; and page 29, line 14 to page 30, line 1 indicate that (4S)-methyl hexanoic KF is more effective against the SK-Hep-1 and HepG2 cell lines which are known to be human liver adenocarcinoma and hepatocellular carcinoma, respectively.

In addition, claims 3-13 were also amended as to the form of the claims. Accordingly, support for these amendments are found in the original claims as filed.

No new matter has been introduced. In light of the foregoing amendments and remarks, Applicants respectfully submit that all of the claims (claims 1-15) are in condition for allowance.

CONCLUSION

Based on the foregoing amendments and remarks, Applicants respectfully request reconsideration and withdrawal of the rejection of claims and allowance of this application.

AUTHORIZATION

The Commissioner is hereby authorized to charge any additional fees which may be required for consideration of this Amendment to Deposit Account No. **13-4500**, Order No. **4126-4026**. A DUPLICATE OF THIS SHEET IS ATTACHED.

In the event that an extension of time is required, or which may be required in addition to that requested in a petition for an extension of time, the Commissioner is requested to grant a petition for that extension of time which is required to make this response timely and is hereby authorized to charge any fee for such an extension of time or credit any overpayment for an extension of time to Deposit Account No. **13-4500**, Order No. **4126-4026**. A DUPLICATE OF THIS SHEET IS ATTACHED.

Respectfully submitted,
MORGAN & FINNEGAN, L.L.P.

Dated: April 25, 2006

By:


Kenneth H. Sonnenfeld / Michael A. Willis
Reg. No. 33,285 / Reg. No. 53,913

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.
3 World Financial Center
New York, NY 10281-2101
(212) 415-8700 Telephone
(212) 415-8701 Facsimile